Resumen
Existen algunos grupos poblacionales en los que el control de la dislipemia todavía presenta algunas dudas. En el presente artículo se revisan las indicaciones del tratamiento hipolipemiante, preferentemente en prevención primaria, en algunos grupos especiales: mujeres, ancianos, infectados con el virus de la inmunodeficiencia humana, pacientes con enfermedad renal crónica y pacientes con síndrome metabólico. Se hace especial hincapié en los datos obtenidos en el estudio JUPITER y otros estudios con rosuvastatina.
Palabras clave
Dislipemia
Mujeres
VIH
Ancianos
Enfermedad renal crónica
Síndrome metabólico
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
S. Mora, R.J. Glynn, J. Hsia, J.G. MacFadyen, J. Genest, P.M. Ridker.
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Circulation, (2010), 121 pp. 1069-1077
[2.]
K. Mizuno, N. Nakaya, Y. Ohashi, N. Tajima, T. Kushiro, T. Teramoto, et al.
Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA).
Circulation, (2008), 117 pp. 494-502
[3.]
J.R. Downs, M. Clearfield, H.A. Tyroler, E.J. Whitney, W. Kruyer, A. Langendorfer, et al.
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA, (1998), 279 pp. 1615-1622
[4.]
G.A. Colditz, M.J. Stampfer, W.C. Willett, B. Rosner, F.E. Speizer, C.H. Hennekens.
A prospective study of parental history of myocardial infarction and coronary heart disease in women.
Am J Epidemiol, (1986), 123 pp. 48-58
[5.]
C.S. Duvernoy, R. Blumentha.
The numbers are in: statins for the primary prevention of cardiovascular disease in women.
Circulation, (2010), 121 pp. 1063-1065
[6.]
S. Lewington, G. Whitlock, R. Clarke, P. Sherliker, J. Emberson, J. Halsey, Prospective Studies Collaboration, et al.
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.
Lancet, (2007), 370 pp. 1829-1839
[7.]
K.M. Anderson, P.W. Wilson, P.M. Odell, W.B. Kannel.
An updated coronary risk profile. A statement for health professionals.
Circulation, (1991), 83 pp. 356-362
[8.]
W. De Ruijter, R.G. Westendorp, W.J. Assendelft, W.P. Den Elzen, A.J. De Craen, S. Le Cessie, et al.
Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study.
BMJ, (2009), 338 pp. a3083
[9.]
R.J. Glynn, W. Koenig, B.G. Nordestgaard, J. Shepard, P.M. Ridker.
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
Ann Intern Med, (2010), 152 pp. 488-496
[10.]
S.J. Zieman, P. Ouyang.
Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention.
Ann Intern Med, (2010), 152 pp. 528-530
[11.]
K.P. Alexander, L.K. Newby, C.P. Cannon, P.W. Armstrong, W.B. Gibler, M.W. Rich, et al.
American Heart Association Council on Clinical Cardiology. Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
Circulation, (2007), 115 pp. 2549-2569
[13.]
S.W. Worm, C. Sabin, R. Weber, P. Reiss, W. El-Sadr, F. Dabis, et al.
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The data collection on adverse events of anti-HIV drugs (D:A:D) study.
J Infect Dis, (2010), 201 pp. 318-330
[14.]
A.G. Coloma, M. Álvarez, A. Roca-Cusachs, l.P. Domingo, M. Puig.
Prevalencia de hipertensión arterial y perfil lipídico en pacientes con infección por el virus de la inmunodeficiencia humana.
Med Clin (Barc), (2008), 131 pp. 681-684
[15.]
B. Grund, J. Neuhaus, A. Phillips, INSIGHTSMART Study Group.
Relative risk of death in the SMART study.
Lancet Infect Dis, (2009), 9 pp. 724-725
[16.]
P. Maggi, T. Quirino, E. Ricci, G.V. De Socio, A. Gadaleta, F. Ingrassia, et al.
Cardiovascular risk assessment in antiretroviral-nave HIV patients.
AIDS Patient Care STDS, (2009), 23 pp. 809-813
[17.]
M.P. Dube, J.H. Stein, J.A. Aberg, C.J. Fichtenbaum, J.G. Gerber, K.T. Tashima, et al.
Adult AIDS Clinical Trials Group Cardiovascular Subcommitte; HIV Medical Association of the Infectious disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Group.
Clin Infect Dis, (2003), 37 pp. 613-627
[18.]
M. Gallego, R. Palacios, J. Ojalla, F. Orihuela, J. Roldán, J. Santos.
por la Sociedad Andaluza de Enfermedades Infecciosas. Concentraciones de colesterol-LDL en una serie de pacientes con infección por VIH.
Med Clin (Barc), (2010), 135 pp. 202-204
[19.]
Recomendaciones de GEAM/SPNS sobre el tratamiento de las alteraciones metabólicas y no metabólicas en el paciente con infección por VIH.
Documento de consenso.
Enf Infecc Microbiol Clin, (2006), 24 pp. 96-117
[20.]
Masana L. Recomendaciones farmacológicas. Fármacos hipolipemiantes. Interacciones farmacológicas. Guía de manejo de la dislipidemia en pacientes infectados por el VIH. Informes, Guías y Recomendaciones de la SEA; 2002 [citado 1 Dic 2002]. Disponible en: http//:www.searteriosclerosis.org
[21.]
E. Aslangul, L. Assoumou, R. Bittar, M.A. Valantin, O. Kalmykova, G. Peytavin, et al.
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
AIDS, (2010), 24 pp. 77-83
[22.]
B. Coll, G. Aragonés, S. Parra, C. Alonso-Villaverde, L. Masana.
Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.
AIDS, (2006), 20 pp. 1675-1677
[23.]
N.B. Shulman, C.E. Ford, W.D. Hall, M.D. Blaufox, D. Simon, H.G. Langford, Hypertension Detection and Follow-up Program Cooperative Group, et al.
Prognostic value of serum creatinine and effect of hypertension on renal function. Results from the hypertension detection and follow-up program.
Hypertension, (1989), 13 pp. 80-93
[24.]
A.D. Hyre, C.S. Fox, B.C. Astor, A.J. Cohen, P. Muntner.
The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipidlowering treatment.
Am J Kidney Dis, (2007), 49 pp. 37-45
[25.]
N.D. Vaziri, H. Moradi.
Mechanisms of dislipidemia of chronic renal failure.
Hemodial Int, (2006), 10 pp. 1-7
[26.]
Heart Protection Study Collaborative Group.
MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-Risk Individuals: a randomized placebo-controlled trial.
Lancet, (2002), 360 pp. 7-22
[27.]
M. Tonelli, L. Moye, F.M. Sacks, B. Kiberd, G. Curhan.
Cholesterol and Recurrent Events Trial I. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.
Ann Intern Med, (2003), 138 pp. 98-104
[28.]
G.F.H. Diercks, W.M.T. Janssen, A.J. Van Boven, A.A.A. Bak, P.E. De Jong, H.J.G.M. Crijns, et al.
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]).
Am J Cardiol, (2000), 86 pp. 635-638
[29.]
M. Tonelli, D. Collins, S. Robins, H. Bloomfield, G.C. Crhan.
Veterans’ Affairs High-Density Lipoprotein Intervention Trial Investigators (VA-HIT). Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency.
Kidney Int, (2004), 66 pp. 1123-1130
[30.]
M.H. Davidson, A. Armani, J.M. McKenney, T.A. Jacobson.
Safety considerations with fibrate therapy.
Am J Cardiol, (2007), 99 pp. C3-C18
[31.]
H. Bays.
Clinical overview of Omacor: a concentrated formulationof omega-3 polyunsaturated fatty acids.
Am J Cardiol, (2006), 98 pp. i71-i76
[32.]
S. Sandhu, N. Wiebe, L.F. Fried, M. Tonelli.
Statins for improving renal outcomes: a meta-analysis.
J Am Soc Nephrol, (2006), 17 pp. 2006-2016
[33.]
US National Institutes of Health. Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients with Progressive Renal Disease (PLANET 1) [citado 1 Sep 2010]. Disponible en: www.clinicaltrials.gov/ct/show/NCT00296374?order=1
[34.]
C. Baigent, M. Landry.
Study of Heart and Renal Protection (SHARP).
Kidney Int Suppl, (2003), 84 pp. S207-S210
[35.]
C. Wanner, V. Krane, G. Ruf, W. Marz, E. Ritz.
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
N Engl J Med, (2005), 353 pp. 238-248
[36.]
B. Fellström, F. Zannad, R. Schmieder, H. Holdaas, A. Jardine, H. Rose, et al.
Effect of rosuvastatin on outcomes in chronic haemodialysis patients design and rationale of the AURORA study.
Curr Control Trials Cardiovasc Med, (2005), 6 pp. 9
[37.]
M. Svensson, E.B. Schmidt, K.A. Jorgensen, J.H. Christensen.
N-3 Fatty Acids as Secondary Prevention Against Cardiovascular Events in Patients Who Undergo Chronic Hemodialysis: a randomized, placebo-controlled intervention trial.
Lin J Am Soc Nephrol, (2006), 1 pp. 780-786
[38.]
M. Edavalath, A. Rees.
Therapy and clinical trials: metabolic syndrome and cardiovascular risk management.
Curr Opin Lipidol, (2008), 19 pp. 438-439
[39.]
K. Winkler, C.B. Ablethauser, C. Gimpelewicz, M. Bortolini, J.L. Isaacsohn.
Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Clin Ther, (2007), 29 pp. 1987-2000
[40.]
M. Arca.
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Drugs, (2007), 67 pp. 43-54
[41.]
P. Deedwania, P. Barter, R. Carmena, J.C. Fruchart, S.M. Grundy, S. Haffner, et al.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Lancet, (2006), 368 pp. 919-928
Copyright ©
2011. Sociedad Española de Cardiología